Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

Breast Cancer: Targets and Therapy

Volumn 6, Issue , 2014, Pages 103-113

  Oostra, Drew R ^a   Macrae, Erin R ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; HER2; Kadcyla ; T DM1; Trastuzumab emtansine

Indexed keywords

ALANINE AMINOTRANSFERASE; BRENTUXIMAB VEDOTIN; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMTUZUMAB OZOGAMICIN; LAPATINIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUBULIN MODULATOR; UNCLASSIFIED DRUG;

ANEMIA; BACKACHE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CARDIOTOXICITY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELLULITIS; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EMBRYOTOXICITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; ANTINEOPLASTIC ACTIVITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; HER2 POSITIVE BREAST CANCER; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; PULMONARY HYPERTENSION; TREATMENT RESPONSE;

EID: 84905272295     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S67297     Document Type: Review

References (59)

1. Giuliano A. Breast Disorders. In: McPhee S, Papdakis M, editors. Current Medical Diagnosis and Treatment. 48th ed. New York: McGraw-Hill; 2009:630-654.
2. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-368.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785): 177-182.
4. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-98.
5. Kumar G, Badve S. Milestones in the discovery of HER2 proto-oncogene and trastuzumab (herceptin). Connections. 2008;13:9-14.
6. Herceptin® (trastuzumab) [prescribing information]. South San Francisco, CA: Genentech; 2014.
7. Tripathy D, Salmon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063-1070.
8. Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
9. Hoffmann-La Roche. A study of trastuzumab emtansine in comparison with treatment of physician's choice in patients with HER2-positive breast cancer who have received at least two prior regimens of HER2-directed therapy (TH3RESA). Available from: http://clinicaltrials.gov/show/NCT01419197. NLM identifier: NCT01419197. Accessed June 18, 2014.
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
11. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3-S8.
12. Hudis C. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
13. American Cancer Society. Breast Cancer Facts and Figures 2011-2012. Atlanta: American Cancer Society; 2012. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf. Accessed June 18, 2014.
14. Olson EM. Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. J Clin Oncol. 2012;30(14):1712-1714.
15. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9(3):1165-1172.
16. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285-4289.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
18. US Food and Drug Administration. FDA expands use of Herceptin for early stage breast cancer after primary therapy [press release]. Silver Spring, MD: US Food and Drug Administration; November 16, 2006. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108788.htm. Accessed April 20, 2014.
19. Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22(4):525-531.
20. Baselga K, Cortes J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trasuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
21. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130.
22. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30(21): 2585-2592.
23. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490-1496.
24. US Food and Drug Administration. Mylotarg (gemtuzumab ozogamicin): market withdrawal [press release]. Silver Spring, MD: US Food and Drug Administration; June 21, 2010. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm. Accessed June 9, 2013.
25. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-568.
26. Pro B, Advani R, Brice P, et al. Brentuxumab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18): 2190-2196.
27. US Food and Drug Administration. FDA approves new treatment for late-stage breast cancer [Internet]. Silver Spring, MD: US Food and Drug Administration; February 22, 2013. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm340704.htm. Accessed June 10, 2013.
28. Girish S, Gupta M, Wang B, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229-1240.
29. Junttila TT1, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347-356.
30. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2011;29(4):351-354.
31. Higashide E, Asai M, Ootsu K, et al. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature. 1977;270(5639):721-722.
32. Yu TW, Bai L, Clade D, et al. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. Proc Natl Acad Sci U S A. 2002;99(12):7968-7973.
33. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, hun901-dm1, by mass spectrometry. Protein Sci. 2005;14(9):2436-2446.
34. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-9290.
35. Erickson HK, Lewis Phillips GD, Leipold DD, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133-1142.
36. Barginear MF, Budman DR. Trastuzumab-DM1: a review of the novel immuno-conjugate for HER2-overexpressing breast cancer. The Open Breast Cancer Journal. 2010;1(1):25-30.\
37. Junutula JR, Flagella KM, Graham RA, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16(19):4769-4778.
38. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16): 2698-2704.
39. Beeram M, Krop IE, Burris HA, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118(23):5733-5740.
40. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398-405.
41. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2 -positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30(26):3234-3241.
42. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157-1163.
43. Kadcyla® (ado-trastuzumab emtansine) [prescribing information]. South San Francisco, CA: Genentech; 2013.
44. US Food and Drug Administration. Safety Alert for Human Medical Products: Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication - Potential Medication Errors Resulting from Name Confusion [press release]. Silver Spring, MD; US Food and Drug Administration; May 6, 2013. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htm. Accessed June 10, 2013.
45. Dang CT, Gianni L, Romieu G, et al. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. J Clin Oncol. 2012;30(Suppl 15):532.
46. Hoffmann-La Roche. A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01641939?term=t-dm1+gastric&rank=1. NLM identifier: NCT01641939. Accessed June 10, 2013.
47. Hoffmann-La Roche. A combination study of trastuzumab emtansine and capecitabine in patients with breast cancer or gastric cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01702558?term=t-dm1+gastric&rank=2. NLM identifier: NCT01702558. Accessed June 10, 2013.
48. Ellis PA, Barrios CH, Im Y, et al. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol. 2011;29(Suppl 15):TPS 102.
49. Hoffmann-La Roche. A study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE). Available from: http://clinicaltrials.gov/show/NCT01772472. NLM identifier: NCT01772472. Accessed June 10, 2013.
50. Dana-Farber Cancer Institute. T-DM1 vs paclitaxel/trastuzumab for Breast (ATEMPT Trial). Available from: http://clinicaltrials.gov/show/NCT01853748. NLM identifier: NCT01853748. Accessed April 30, 2014.
51. Hoffmann-La Roche. A study of Kadcyla (trastuzumab emtansine) in patients with HER2 positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment. Available from: http://clinicaltrials.gov/show/NCT01702571. NLM identifier: NCT01772472. Accessed June 10, 2013.
52. Hoffmann-La Roche. A study of kadcyla (trastuzumab emtansine) plus perjeta (pertuzumab) following anthracyclines in comparison with herceptin (trastuzumab) plus perjeta and a taxane following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. Available from: http://clinicaltrials.gov/show/NCT01966471. NLM identifier: NCT01966471. Accessed April 30, 2014.
53. Abraham J. Trastuzumab emtansine in advanced HER2-positive breast cancer. Community Oncology. 2013;10(3):71-73.
54. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24(6):1526-1533.
55. Olson EM, Lin NU, DiPiro PJ, et al. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012;23(1): 93-97.
56. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol. 2014;116(1):205-206.
57. Tessari A, Palmieri D, Di Cosimo S. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med. 2013;7:1-19.
58. Baselga J, Verma S, Ro J, et al. Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Cancer Res. 2013;73(8, Supplement 1):LB-63.
59. ClinicalTrials.gov [homepage on the Internet]. Bethesda: US National Institutes of Health; 2014 [updated April 29, 2014]. Available from: http://clinicaltrials.gov/ct2/home.Accessed April 30, 2014.